Table 1.

RGD-modified nanoparticles.

Name	Ligand	Carrier	Therapeutics	Cancer Type	Ref
SSLD	cRGDfK and cRGDyC	LP	DOX	colon and melanoma	[20]
cRGD-PAMAM	cRGDyC peptide	PAMAM dendrimer	fluorescence	breast cancer	[22]
RGD-KLA/PTX-Lips	cRGDyK	LP	PTX, KLA peptide	breast cancer	[23]
PLGba	cRGDyK	LP	Galbanic acid	colon cancer	[25]
cRGD-PAMAM	cRGDyC	PAMAM dendrimer	arsenic trioxide	orthotopic glioma	[28]
c(RGDyC)-LP	cRGDyK	LP	sodium borocaptate	glioma	[30]
RGD-heparin	cRGD	self-assembled heparin	heparin	ovarian cancer (vasculogenic mimicry)	[31]
RGD-MEND	cRGDfK	lipid nanoparticle	siRNA against VEGFR2	renal cell carcinoma, lung metastasis model	[32,33]
iRGD-MSN	iRGD	MSN	DOX, CA4	cervical cancer	[34]